Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerobic Exercise and Duloxetine in Knee Osteoarthritis and Depression
NCT04111627Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duloxetine in knee osteoarthritis (OA) and major depressive disorder (MDD), sponsored by University of Maryland, Baltimore. Primary endpoints: Knee Osteoarthritis Outcomes Scale Pain Subscale at 12 weeks and Hamilton Depression Rating Scale at 12 weeks. Started Oct 2021; status: completed.
02
Drugs
duloxetine
03
Conditions
knee osteoarthritis (OA)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04111627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111627.